Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Once this overhang clears it will shoot up
Cov yep thanks to Woodys mess up
Jarv55 Could well do after the FDA meeting in Q1 this year. What i like is a lot of the work done here has been paid for when the SP was over £2/£3. We get to buy at 40p.
easy 20% plus today
I now wonder if the company is now in danger of getting a low bid.
Pre market USA is up 19% so looking good
I now wonder if this company will now start to attract some positive press. Plenty will now be looking to give this some value. IMO
I stated when we got the 2b Asteroid RNS nov 2019 that it was good news. This is confirmation all is still on track. I really hope they have success with this as it's geared towards children.Well done MPH
As part of the PRIME pathway, Mereo has discussed the results of the Phase 2b ASTEROID study with the EMA. On the basis of the Phase 2b data, the EMA supports the initiation of the planned pivotal pediatric study in Europe on the basis of the previously approved pediatric investigational plan (PIP). This is based on a primary endpoint of fracture rate over a 12-month period in approximately 165 children aged 5 to <18 years old.
Huge buys more to come with so much research in the pipeline.
13-Jan-20 16:32:35 42.65625 800,000 Buy* 341.25k O
Been tree shaking to fill BIG buys?
GLA
Plenty going on at MPH
Mereo's broader pipeline consists of four additional clinical-stage product candidates; acumapimod for the treatment of acute exacerbations of chronic obstructive pulmonary disease ("AECOPD"), leflutrozole for the treatment of hypogonadotropic hypogonadism ("HH") in obese men, navicixizumab for the treatment of platinum-resistant ovarian cancer (recently licensed to Oncologie), and etigilimab for patients with advanced or metastatic solid tumors.
If the yanks like it we get the funding, not long to wait.
Boom time was getting nervous
Nasdaq gonna love that rns this is big nowm
Mereo expects to conduct a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in Q1 2020 to discuss the data from the Phase 2b ASTEROID study as well as the proposed pediatric pivotal study design. Mereo intends to announce the outcome of these discussions following the meeting.
Come on you beauty. Start reacting to some decent news.
There are no currently approved therapies for osteogenesis imperfecta, and treatment options are greatly needed."
This is big news , "We believe these additional endpoint data, together with the totality of the 12-month topline data and trend in fracture rate reduction in the high dose cohort, are fully supportive of moving forward with our planned pivotal trial in children with OI. To this end, we have made additional progress on the regulatory front, including a positive recent meeting with the European Medicines Agency ("EMA"), and are currently preparing for a Type B End-of-Phase 2 meeting with the FDA, scheduled for the first quarter of 2020."
Hope price reacts accordningly
of rather large trades just come through from yesterday. Showing as buys?
I’m no scientist, but to me that sounds like the drugs work very well! Here’s to the next study! And more positive results!!
emm to say your not worried must be on your mind ?
Exactly the same thing happened over at TRX I’m not worried at all.
Painful tree shake need to look away for a bit but, things can change rapidly here.
Just dropped again. This was higher on 9 of the last 11 trading days.
I'm zoomed into the chart and the price hasn't been lower in the last 11 trading days.
On 27th and 30th Dec it was 47p (hit 50p on 30th Dec).
Link Fund and Schroders still held then. Is this a prolonged tree shake?